Sharon Mates compensation by year
Intra-Cellular Therapies Summary Compensation Table · all 3 fiscal years held| Component | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
| Salary | $793,638 | $849,193 | $891,653 |
| Bonus | $1,428,548 | $1,358,709 | $1,426,645 |
| Stock awards | $3,500,012 | $4,899,997 | $7,749,984 |
| Option awards | $1,499,978 | $2,099,991 | $0 |
| Non-equity incentive | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $23,767 | $24,967 | $18,131 |
| Total | $7,245,943 | $9,232,857 | $10,086,413 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Intra-Cellular Therapies, Inc. DEF 14A filed April 29, 2024, accession 0001628280-24-018986, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Intra-Cellular Therapies, Inc. filed document, accession 0001628280-24-018986. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 122,137 | $8,747,452 | — |
| RSU | 41,131 | $2,945,802 | — |
| PSU | 40,712 | $2,915,793 | — |
| PSU | 27,108 | $1,941,475 | — |
| PSU | 24,678 | $1,767,438 | — |
| RSU | 22,590 | $1,617,896 | — |
| Option | 33,445 | — | $56.73 |
| Option | 17,824 | — | $36.89 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Intra-Cellular Therapies, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
29 Form 4 lines since the FY2023 proxy (filed April 29, 2024)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2025-04-02 | Disposition to the issuer derivative | — | 135,399 | — | 0 |
| 2025-04-02 | Disposition to the issuer derivative | — | 121,212 | — | 0 |
| 2025-04-02 | Disposition to the issuer derivative | — | 86,003 | — | 0 |
| 2025-04-02 | Disposition to the issuer | — | 190,000 | $132.00 | 0 |
| 2025-04-02 | Disposition to the issuer derivative | — | 66,886 | — | 0 |
| 2025-04-02 | Disposition to the issuer derivative | — | 138,473 | — | 0 |
| 2025-04-02 | Disposition to the issuer | — | 945,235 | $132.00 | 0 |
| 2025-04-02 | Grant or award derivative | — | 40,712 | $0.00 | 40,712 |
The 8 most recent of 29 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Intra-Cellular Therapies’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Sharon Mates · this page | Chairman and Chief Executive Officer | $10,086,413 |
| Mark Neumann | Executive Vice President, Chief Commercial Officer | $3,543,028 |
| Michael Halstead | President | $3,526,233 |
| Suresh Durgam | Executive Vice President, Chief Medical Officer | $3,511,175 |
| Lawrence Hineline | Senior Vice President of Finance, Chief Financial Officer, Treasurer and Assistant Secretary | $3,361,110 |
Board service
Intra-Cellular Therapies board · FY2023How this board is paid
Company policy: Intra-Cellular Therapies pays directors a $50,000 cash retainer and $675,000 in RSUs/Options. As stated in Intra-Cellular Therapies's FY2023 proxy.
The full Intra-Cellular Therapies compensation record
free company briefThis page is one person within Intra-Cellular Therapies's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Intra-Cellular Therapies proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Intra-Cellular Therapies's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.